KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
Gregory D JonesRaul CasoKay See TanBrooke MastrogiacomoFrancisco Sanchez-VegaYuan LiuJames G ConnollyYonina R Murciano-GoroffMatthew J BottPrasad S AdusumilliDaniela MolenaGaetano RoccoValerie W RuschSmita SihagSandra MisaleRona YaegerAlexander E DrilonKathryn C ArbourGregory J RielyNeal X RosenPiro LitoHaiying ZhangDavid C LydenCharles M RudinDavid R JonesBob T LiJames M IsbellPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
KRAS G12C mutations are associated with worse DFS after complete resection of stage I-III lung adenocarcinoma. These tumors harbor more aggressive clinicopathologic and genomic features than other KRAS-mutant tumors. We identified a high-risk group for whom KRAS G12C inhibitors may be investigated to improve survival.